• August 13, 2018 • 7:00 AM EDT
HONOR Study Results to be Included in Poster Presentation at a Scientific Conference in…
Read moreOur experienced team has a strong track record of success in drug approvals and value creation.
View ManagementTonix's lead product candidate, Tonmya, is being developed for the treatment of PTSD.
View PipelineTonix is developing innovative pharmaceutical products to address important public health challenges, with two programs focusing on posttraumatic stress disorder (PTSD). PTSD is a serious condition characterized by chronic disability, inadequate treatment options, and overall high utilization of healthcare services creating significant economic burden. Other development programs include TNX-801, a potential smallpox-preventing vaccine.
Learn more about tonix